An updated report of the RUBY trial included the results on 21 SCD patients supporting the efficacy of EDIT-301 (renamed as Reni-Cel): total Hb was 14.2 ± 2 g/dL at month 6 and was maintained up to last follow-up; mean percentage of HbF was 48.2% at month 6 and was maintained at >40% through last follow-up; markers of hemolysis improved or normalized; all patients were vascular event-free [108]. The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.